196 related articles for article (PubMed ID: 23079576)
1. Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway.
Joshi H; Bhanot G; Børresen-Dale AL; Kristensen V
Br J Cancer; 2012 Nov; 107(10):1722-8. PubMed ID: 23079576
[TBL] [Abstract][Full Text] [Related]
2. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
4. Mutated
Li AM; Boichard A; Kurzrock R
Cancer Biol Ther; 2020; 21(1):95-100. PubMed ID: 31564192
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
[TBL] [Abstract][Full Text] [Related]
6. TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study.
Hurson AN; Abubakar M; Hamilton AM; Conway K; Hoadley KA; Love MI; Olshan AF; Perou CM; Garcia-Closas M; Troester MA
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):124-131. PubMed ID: 34737209
[TBL] [Abstract][Full Text] [Related]
7. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer.
Rønneberg JA; Fleischer T; Solvang HK; Nordgard SH; Edvardsen H; Potapenko I; Nebdal D; Daviaud C; Gut I; Bukholm I; Naume B; Børresen-Dale AL; Tost J; Kristensen V
Mol Oncol; 2011 Feb; 5(1):61-76. PubMed ID: 21212030
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.
Aas T; Geisler S; Eide GE; Haugen DF; Varhaug JE; Bassøe AM; Thorsen T; Berntsen H; Børresen-Dale AL; Akslen LA; Lønning PE
Eur J Cancer; 2003 Mar; 39(4):438-46. PubMed ID: 12751373
[TBL] [Abstract][Full Text] [Related]
9. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.
Ungerleider NA; Rao SG; Shahbandi A; Yee D; Niu T; Frey WD; Jackson JG
Breast Cancer Res; 2018 Oct; 20(1):115. PubMed ID: 30285883
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
Győrffy B; Bottai G; Lehmann-Che J; Kéri G; Orfi L; Iwamoto T; Desmedt C; Bianchini G; Turner NC; de Thè H; André F; Sotiriou C; Hortobagyi GN; Di Leo A; Pusztai L; Santarpia L
Mol Oncol; 2014 May; 8(3):508-19. PubMed ID: 24462521
[TBL] [Abstract][Full Text] [Related]
14. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
[TBL] [Abstract][Full Text] [Related]
16. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
17. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
18. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
19. TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
Mukhopadhyay UK; Oturkar CC; Adams C; Wickramasekera N; Bansal S; Medisetty R; Miller A; Swetzig WM; Silwal-Pandit L; Børresen-Dale AL; Creighton CJ; Park JH; Konduri SD; Mukhopadhyay A; Caradori A; Omilian A; Bshara W; Kaipparettu BA; Das GM
J Natl Cancer Inst; 2019 Nov; 111(11):1202-1215. PubMed ID: 30990221
[TBL] [Abstract][Full Text] [Related]
20. TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.
Ragu ME; Lim JMC; Ng PS; Yip CH; Rajadurai P; Teo SH; Pan JW
Breast Cancer Res; 2023 Apr; 25(1):48. PubMed ID: 37101199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
